# Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty

> **NCT01358669** · PHASE2 · COMPLETED · sponsor: **Sheffield Teaching Hospitals NHS Foundation Trust** · enrollment: 24 (actual)

## Conditions studied

- Revision Surgery of Total Hip Arthroplasty

## Interventions

- **DRUG:** Denosumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01358669
- **Lead sponsor:** Sheffield Teaching Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-14
- **Primary completion:** 2019-01-02
- **Final completion:** 2021-12-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358669, "Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01358669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*